Impressive mOS in PD-l1 positive patients (maybe 60-70% of overall pop).
In this setting, EFTI outperforming the chemo/CTLA-4 combos.
Add today's impressive mOS data to the already impressive ORR mPFS, mDoR makes EFTI hard to ignore.
Does Merck decide to take EFTI to protect its Keytruda? or does one of the other 6 Big Pharma who own a PD-(L)1 asset swoop in to start carving out some market share in these big cancer indications? Or does EFTI continue to go unnoticed and unloved
We've seen big pharma transactions with companys with less compelling/early data.....
Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC, page-3
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 211685 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 279000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |